Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Roginolisib in Uveal Melanoma: NCT07203391 Clinical Landscape Report 2026
28 September 2026
NCT07203391 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abemaciclib in ER Positive Endometrial Carcinoma: NCT07209449 Clinical Landscape Report 2026
28 September 2026
NCT07209449 clinical landscape for ER Positive Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Anlotinib Dihydrochloride in Locally Advanced Soft Tissue Sarcoma: NCT07205185 Clinical Landscape Report 2026
28 September 2026
NCT07205185 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
i15.NKG2D.zeta-NK cells(Baylor College of Medicine) in Neuroblastoma recurrent: NCT07211737 Clinical Landscape Report 2026
28 September 2026
NCT07211737 clinical landscape for Neuroblastoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
THEO-260 in Ovarian Cancer: NCT07211659 Clinical Landscape Report 2026
28 September 2026
NCT07211659 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Surovatamig in Large B-cell lymphoma: NCT07215585 Clinical Landscape Report 2026
28 September 2026
NCT07215585 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[68Ga]FAPI-46 in Malignant melanoma stage IV: NCT07215182 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.sutd.idm.oclc.org/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
9 min read
[68Ga]FAPI-46 in Malignant melanoma stage IV: NCT07215182 Clinical Landscape Report 2026
28 September 2026
NCT07215182 clinical landscape for Malignant melanoma stage IV: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RP-2(Replimune Group) in Metastatic Renal Cell Carcinoma: NCT07218692 Clinical Landscape Report 2026
28 September 2026
NCT07218692 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT07220187 Clinical Landscape Report 2026
28 September 2026
NCT07220187 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab in Ovarian Cancer: NCT07216105 Clinical Landscape Report 2026
28 September 2026
NCT07216105 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Childhood Rhabdomyosarcoma: NCT07222735 Clinical Landscape Report 2026
28 September 2026
NCT07222735 clinical landscape for Childhood Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SC-CAR.GPC3xIL15.21 CAR T cells(Seattle Children's Hospital) in Hepatocellular Carcinoma: NCT07224568 Clinical Landscape Report 2026
28 September 2026
NCT07224568 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.